Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells
about
Monoclonal antibodies in gynecological cancer: a critical point of view.Efficient blockade of Akt signaling is a determinant factor to overcome resistance to matuzumab.In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruptionA phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA statusEpidermal growth factor receptor as a biomarker for cervical cancer.Emerging antibody combinations in oncology.A 4-Phenoxyphenol Derivative Exerts Inhibitory Effects on Human Hepatocellular Carcinoma Cells through Regulating Autophagy and Apoptosis Accompanied by Downregulating α-Tubulin Expression.A fusogenic dengue virus-derived peptide enhances antitumor efficacy of an antibody-ribonuclease fusion protein targeting the EGF receptor.A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I.Cetuximab induces eme1-mediated DNA repair: a novel mechanism for cetuximab resistance.Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer.Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay.Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer.
P2860
Q35659915-380DD5D3-7CBA-4DAD-AC74-2034E45708F0Q35808930-D59E9F6C-49DA-48FE-A57B-89EEE54D3E35Q35836035-878F669D-3129-449C-BEEE-83858DBA15C6Q35836433-E86948FA-CB4E-4CD5-BF3A-85089FA4E59BQ37575182-291D9FAA-CF7D-4214-AC2A-ECE42B4ECACBQ37843137-8BD94A40-04A3-4C1D-AA7C-2F3987685596Q37893414-45CE058E-4E66-42D0-B35F-D3321FBB0E63Q38680790-0ED191C8-3ADB-4424-B43C-9D55FDA5B24DQ38949177-624CDD42-277C-4E54-90E8-0B2B9A677ABFQ39748979-E61C3E8D-1744-4C87-8A33-52CDDAD19643Q41816821-EDDCC9B9-E82D-4B4E-89C7-BD480DA47637Q47095819-CD88214E-B495-4DCD-B588-49B85BC7D7F2Q51749302-850E764E-96D2-41F8-88A0-212B45083E74Q53093760-A857F5D3-D154-4114-B012-197530521F0E
P2860
Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combination of cetuximab with ...... ation of cervical cancer cells
@en
Combination of cetuximab with ...... tion of cervical cancer cells.
@nl
type
label
Combination of cetuximab with ...... ation of cervical cancer cells
@en
Combination of cetuximab with ...... tion of cervical cancer cells.
@nl
prefLabel
Combination of cetuximab with ...... ation of cervical cancer cells
@en
Combination of cetuximab with ...... tion of cervical cancer cells.
@nl
P2093
P2860
P356
P1476
Combination of cetuximab with ...... ation of cervical cancer cells
@en
P2093
C G Ferreira
J S Mororó
L Bardella
R L A Silva
R M Albano
V H de Almeida
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605216
P407
P577
2009-08-04T00:00:00Z